REGENXBIO (RGNX) presented an update on its clinical pipeline and financial position at the 2026 Global Healthcare Conference on September 15, 2026, highlighting progress on its Duchenne muscular dystrophy gene therapy candidate and a diabetic retinopathy program partnered with AbbVie.
The company reported pro forma cash of $313 million at the end of its most recent quarter, with a current ratio of 2.86. Management said that figure would fund operations into the fourth quarter of 2027, aligning with the expected Prescript Drug Use Act filing date for RGX-202. Additional AbbVie milestone payments, priority review voucher sales, or product revenue could extend the runway into 2028, though those were excluded from the base-case projection. Over the trailing twelve months, levered free cash flow was negative $250 million, according to InvestingPro data.
RGX-202, an AAV-based gene therapy for Duchenne muscular dystrophy, has completed enrollment in both its pivotal study—63 patients—and a 30-patient confirmatory trial. The company stated it now holds roughly ten times more data than it did at its end-of-Phase 2 meeting with the FDA. A pre-BLA meeting was planned for late 2024, with a BLA filing targeted for Q1 2025 and an expected PDUFA decision around Q4 2027.
"We have been in business for roughly 15 years, working on AAV, primarily AAV8 and AAV9," said Curran, an REGENXBIO executive. "We are probably the only company to be able to make high-dose AAV at 80% full capsid, which I think is extremely appealing to FDA." Steve, another REGENXBIO executive, noted that the correlation between NSAA measurements and microdystrophin levels in the RGX-202 program reached approximately 0.9, substantially stronger than previously observed in the space.
In ophthalmology, REGENXBIO's Sirvac program for wet age-related macular degeneration is advancing through two Phase III trials, each enrolling more than 600 patients, with top-line data expected in Q4. The company projected a greater than 50% reduction in injection burden versus existing anti-VEGF therapies, building on prior studies suggesting a 70%-plus decline.
The ABBV-RGX-314 diabetic retinopathy program received a $100 million AbbVie milestone payment tied to its indication, with a smaller submission milestone also anticipated. Data from the ALTITUDE trial showed a 70% reduction in vision-threatening complications over two-and-a-half years, while the ongoing NAAVIGATE Phase IIb study continues to enroll.
The NAVSUNLI program targeting Hunter syndrome remains in development, with some patients having received treatment three to five years ago. Referred competitor therapy ELEVIDYS was noted in the Duchenne space.
REGENXBIO's shares traded around $8.53–$8.69 on the day of the conference, down roughly 40% year to date. The company's market capitalization stood at approximately $574 million. Analyst price targets ranged from $10 to $50, according to data cited by Baird senior biotech analyst Bryan Skorney, who moderated the session.
Product launches and commercial infrastructure buildout are anticipated around 2027–2028, depending on regulatory outcomes.
